Medy-Tox Inc.

Medy-Tox Inc.

Share · KR7086900008 (XKOS)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Medy-Tox Inc.
No Price
Closing Price XKOS 29.04.2026: 108.600,00 KRW
29.04.2026 06:30
Current Prices from Medy-Tox Inc.
ExchangeTickerCurrencyLast TradePriceDaily Change
XKOS: KOSDAQ
KOSDAQ
086900.KQ
KRW
29.04.2026 06:30
108.600,00 KRW
1.100,00 KRW
+1,02 %
Share Float & Liquidity
Free Float 69,45 %
Shares Float 4,57 M
Shares Outstanding 6,58 M
Invested Funds

The following funds have invested in Medy-Tox Inc.:

Fund
iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF USD (Dist)
Vol. in million
96,92
Percentage (%)
0,09 %
Fund
iShares MSCI EM IMI ESG Screened UCITS ETF USD (Dist)
Vol. in million
36,19
Percentage (%)
0,01 %
Fund
iShares MSCI EM IMI ESG Screened UCITS ETF USD (Acc)
Vol. in million
183,22
Percentage (%)
0,01 %
Company Profile for Medy-Tox Inc. Share
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual and Recell Ice for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method; and Careveam for treating skin ailment by using ultraviolet light. Further, the company offers Neurakin cream for acute eczema, contact dermatitis, atopic dermatitis, chronic eczema, rosacea dermatitis, perioral dermatitis, herpes zoster, and acne vulgaris. It also exports its products to approximately 60 countries, including Japan, Thailand, and Brazil. Medytox, Inc. has partnership with Dyadic International, Inc. to develop vaccines against COVID-19 variants. The company was founded in 2000 and is headquartered in Cheongju, South Korea.

Company Data

Name Medy-Tox Inc.
Company Medy-Tox Inc.
Website https://www.medy-tox.co.kr
Primary Exchange XKOS KOSDAQ
ISIN KR7086900008
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Hyun-Ho Jung
Market Capitalization 707 Mrd.
Country South Korea
Currency KRW
Employees 0,7 T
Address 78, Gak-ri 1-gi, Cheongju
IPO Date 2009-01-16
Dividends from 'Medy-Tox Inc.'
Ex-Date Dividend per Share
29.09.2025 1.200,00 KRW
27.09.2024 1.100,00 KRW
26.09.2023 952,38 KRW
29.09.2022 1.050,00 KRW
29.09.2021 1.000,00 KRW
28.09.2020 1.050,00 KRW
27.09.2019 747,39 KRW
27.09.2018 726,33 KRW
27.12.2017 1.129,84 KRW
28.09.2017 645,63 KRW

Stock Splits

Date Split
28.12.2022 21:20
29.12.2021 21:20
29.12.2020 20:21
27.12.2019 8240:9261
27.12.2018 515000:596177
29.12.2009 257500:307031

Ticker Symbols

Name Symbol
KOSDAQ 086900.KQ
More Shares
Investors who hold Medy-Tox Inc. also have the following shares in their portfolio:
Black Peony (Group) Co., Ltd.
Black Peony (Group) Co., Ltd. Share
GENTIAN DIAGNOST. NO -,01
GENTIAN DIAGNOST. NO -,01 Share